News

RBX2660 was originally approved by the FDA in 2022 and came to market in January 2023.

Rates of key safety events, such as malignancies and major adverse cardiovascular events, were comparable among patients receiving placebo and ustekinumab.

Recent studies have indicated that using adenoma per colonoscopy as a metric could help better forecast the risk of colon cancer.

Patients with IBD who were treated with advanced therapies who obtained clinical remission had 1.6 times more likely to maintain remission when compared with those who achieved clinical response without remission.

Intravitreal brolucizumab and aflibercept in eyes with nAMD were each linked to a significant decrease in the ocular blood flow 30 minutes after injection.

According to the study, these findings can inform policy decisions and assist in developing interventions aimed at reducing absenteeism and promoting the productivity of individuals with idiopathic inflammatory rheumatic diseases.

Data from patients with eGFR of 20 mL/min/1.73m2 or less from the ADVOCATE trial provide new insight into the effects of avacopan use in patients with lower baseline eGFRs.

A proportion of patients reported triggering or worsening symptoms after a meal, with the largest proportion experiencing bloating or distention, followed by abdominal pain or discomfort, and epigastric pain.

After spesolimab was found to be useful against generalized pustular psoriasis, this new analysis showed promising results for the treatment despite differences in demographics and other characteristics.

New data indicates a connection between post-surgery cognitive declines and delirium, though future research may be needed to understand the causal pathway.

No statistically significant differences in infusion reaction, serious reaction, or immunogenicity rates were identified between patients switching to an infliximab biosimilar and those who continued treatment on the originator.

The risk of developing high grade dysplasia or esophageal adenocarcinoma was higher in patients with Barrett’s esophagus with immunosuppressant medication use.

No statically significant differences in ESR, CRP, TNF levels, and albumin were observed pre- and post-switch from the infliximab originator to the biosimilar.

At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.

Small molecule therapies offer patients with mild or moderate inflammatory bowel disease a much cheaper alternative to biologics.

Artificial intelligence is being used to help detect polyps for patients undergoing a colonoscopy.

An analysis of national data shows Asian and male patients are at worse risk of mortality, however.

An analysis of data obtained from urine samples in the MUSE and TULIP-1 trial sheds new light on the clinical utility of the RAIL score for identifying disease activity and treatment responders in SLE patients with and without lupus nephritis, respectively

CCR East 2023 data show ixekizumab bettered adalimumab on measures of joint pain and quality of life in patients with PsA and concomitant nail plus DIP involvement.

An analysis of Medcare claims data offers clinicians an overview or the effectiveness of sarilumab and tocilizumab in second- and third-line polymyalgia rheumatica treatments relative to conventional immunomodulators, such as methotrexate or azathioprine.

Post-hoc analysis from DISCOVER-2 show patients who achieve a clinical response by week 8 generally go on to see quality-of-life improvements past 1 year.

An analysis of data from the National Inpatient Sample offers an overview of risk for adverse delivery outcomes associated with Takayasu arteritis among a real-world cohort of US-based patients.

A diet that is high in sugar, fried foods, and lacks vegetables increases the risk of pediatric inflammatory bowel disease.

Clinical outcomes of lab values were not statistically different in changes from baseline to 12 months between children with inflammatory bowel disease initiated on the TNF originator or biosimilar.

Patients with moderate to severe PCM to go along with the AAH were significantly more likely have a number of vitamin deficiencies, including in vitamin D, vitamin B12, and folate.

Results highlight the need for physicians to consider rheumatoid arthritis in patients with microscopic colitis presenting with arthralgia or other joint symptoms.

An analysis of 11 late-stage clinical trials shows guselkumab provides a consistent and comparable safety profile to placebo in treated patients.

Therapies including biologics and corticosteroids were more frequently used among patients with rheumatoid arthritis and lupus who developed severe COVID-19.

Dupilumab became the first approved treatment for eosinophilic esophagitis in 2022.

Chronic tophaceous gout was demonstrated to be an independent risk factor linked to the development of colorectal cancer.